-+ 0.00%
-+ 0.00%
-+ 0.00%

Hansa Biopharma Seeks US FDA Nod for Guillain-Barré Syndrome Treatment

MT Newswires·10/21/2026 00:31:33
Listen to the news
12:31 AM EDT, 10/21/2026 (MT Newswires) -- Hansa Biopharma (HNSA.ST) filed an investigational new drug application with the US Food and Drug Administration for its IgG-cleaving enzyme HNSA-5487, being developed to treat Guillain-Barré syndrome. The application marks a step towards the clinical testing of HNSA-5487 in GBS patients, according to a Tuesday release. Subject to FDA review, the biopharmaceutical company plans to launch a small, single-ascending-dose phase 2a study in GBS patients, followed by a pivotal trial.